From what 7 stock analysts predict, the share price for Lantheus Holdings Inc (LNTH) might increase by 68.31% in the next year. This is based on a 12-month average estimation for LNTH. Price targets go from $80.00 to $114.00. The majority of stock analysts believe LNTH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assignedLNTH 7 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Lantheus Holdings Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on LNTH. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
david turkaly JMP Securities | Buy | $100.0 | reiterated | Jan 23, 2024 |
anthony petrone Mizuho Securities | Buy | $90.0 | maintained | Jan 23, 2024 |
justin walsh JonesTrading | Buy | $114.0 | maintained | Jan 11, 2024 |
roanna ruiz Leerink Partners | Buy | None | rated | Jan 10, 2024 |
richard newitter Truist Financial | Buy | $80.0 | maintained | Dec 19, 2023 |
andy hsieh William Blair | Hold | None | downgraded | Dec 18, 2023 |
matthew taylor Jefferies | Buy | $110.0 | maintained | Dec 18, 2023 |
boris peaker TD Cowen | Buy | $83.0 | maintained | Dec 18, 2023 |
kemp dolliver Brookline Capital Markets | Buy | $100.0 | initiatedcoverage | Nov 30, 2023 |
yuan zhi B.Riley Financial | Buy | $113.0 | reiterated | Nov 2, 2023 |
danielle antalffy SVB Securities | Buy | $100.0 | reiterated | May 17, 2022 |
zachary weiner Jefferies | Buy | $60.0 | rated | Mar 14, 2022 |
erin wright Morgan Stanley | Hold | $26.0 | maintained | Jul 28, 2021 |
raj denhoy Jefferies | Buy | $29.0 | initiatedcoverage | Jun 29, 2020 |
lawrence solow CJS Securities | Hold | $24.0 | downgraded | Oct 3, 2019 |
larry biegelsen Wells Fargo | Buy | $20.0 | reiterated | Aug 2, 2018 |
travis steed Bank of America Securities | Buy | $22.0 | rated | Sep 27, 2017 |
glenn novarro RBC Capital | Buy | $12.0 | reiterated | Jan 20, 2017 |
matthew keeler Truist Financial | Hold | $4.0 | reiterated | Aug 5, 2016 |
jeff johnson Robert W. Baird | Hold | None | reiterated | Apr 11, 2016 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
When did it IPO
2015
Staff Count
698
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Ms. Mary Anne Heino
Market Cap
$3.94B
In 2023, LNTH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that LNTH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
PGNY-USD
$40.78
EXPO-USD
$76.86
LOPE-USD
$130.07
AXSM-USD
$80.47
COLB-USD
$18.28
IPGP-USD
$86.28